By 2021 it will be distributed also in Europe

Italy, Capua (CE), February 8th, 2021 – Pierrel S.p.A, a full-service global provider for life science, biopharma and pharmaceutical industries listed on the Italian Stock Exchange has announced the marketing of the Orabloc Needlestick Safety System in the U.S., through Patterson Dental.
The system is a single-use needle protection device that covers the end of needles after use to minimize the risk of needle sticks. The device is designed to also meet CDC and OSHA requirements for one-handed needle containment.

The device is preloaded with 100 color-coded capsules that can be used with all needle lengths and gauges. It can also be used with bent or angled needles. The Orabloc Needlestick device adopts an easy-to-use, spring-loaded system that automatically advances to the next capsule after one capsule is removed. The color coding provides a visual notification when the device is running low on capsules. The Orabloc safety device helps protect against accidental needle sticks during recapping and temporary storage or when disposing of the needle in a sharp’s container. It also has a non-skid silicone bottom to ensure stability on any surface while allowing for portability.

The Orabloc Needlestick Safety System joins the injectable dental anesthetic, Orabloc, marketed in the U.S. since 2011, and redefines needle stick safety protocol. Branding the device as a private label of a patented product, Orabloc, the Needlestick Safety System builds upon the product franchise.

“This innovative device is a product extremely in line with the current market needs for greater secutity and is a safe and practical alternative to current methods available for supporting compliance of the OSHA Bloodborne Pathogen standards” said Fabio Velotti, CEO of Pierrel Pharma.

For more information, visit orabloc.com/orabloc-needlestick-safety-system

About Pierrel S.p.A.
Pierrel S.p.A. listed on the Italian Stock Exchange since May 2006, is today a full-service global provider for life science, biopharma and pharmaceutical industries. Pierrel Group, through its two business Divisions, is specialized inpharmaceutical manufacturing (Contract Manufacturing Division), and in the development, registration and licensing of new drugs and medical devices (Pharma Division). The company has over 60 years’ experience in the pharmaceutical industry and is one of the leading European manufacturers of local and dental anaesthetics. The manufacturing site has a modern aseptic production line, approved by AIFA and FDA, and regularly inspected by these two agencies.
The subsidiary Pierrel Pharma S.r.l. has registered and distributes dental anaesthetic Orabloc^® in Canada, USA, Russia and Europe.
Pierrel S.p.A head quarter is located in Italy in Capua (CE) near Naples.
www.pierrelgroup.com